2016 Genitourinary Cancers Symposium Press Program to Feature Research Advances in Prostate and Kidney Cancers

For immediate release
November 25, 2015
Contact
Alise Fisher
571-483-1354
alise.fisher@asco.org

ALEXANDRIA, Va. – Co-sponsors of the 2016 Genitourinary Cancers Symposium announced today three abstracts that will be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, January 4, from 12:00 noon – 1:30 PM (ET).

The following studies will be featured during the presscast:

- A subgroup analysis from a phase III trial comparing cabozantinib to everolimus in patients with advanced kidney cancer (Abstract 499).
- A large study evaluating the association between regular aspirin use and the risk of lethal prostate cancer (Abstract 306).
- A study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).

The 2016 Genitourinary Cancers Symposium will take place January 7-9 at the Moscone West Building in San Francisco, California. Abstracts presented at the Symposium will discuss the latest strategies in the prevention, screening, diagnosis, and treatment of prostate, kidney, testicular, and urothelial cancers. On-site facilities for reporters will include a working newsroom and access to leading experts in genitourinary cancers.

Visit the 2016 Genitourinary Cancers Symposium Media Resource Center for instructions on how to register for the meeting, as well as how to participate in the presscast.

Three leading medical specialty societies co-sponsor the Symposium: the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO).
About ASCO:

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.